Free Trial
NASDAQ:NEO

NeoGenomics (NEO) Stock Price, News & Analysis

NeoGenomics logo
$7.21 +0.13 (+1.84%)
Closing price 04:00 PM Eastern
Extended Trading
$7.34 +0.13 (+1.73%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NeoGenomics Stock (NASDAQ:NEO)

Key Stats

Today's Range
$6.95
$7.23
50-Day Range
$4.84
$7.62
52-Week Range
$4.72
$19.11
Volume
2.54 million shs
Average Volume
2.16 million shs
Market Capitalization
$931.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.75
Consensus Rating
Hold

Company Overview

NeoGenomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

NEO MarketRank™: 

NeoGenomics scored higher than 70% of companies evaluated by MarketBeat, and ranked 310th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NeoGenomics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 8 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NeoGenomics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about NeoGenomics' stock forecast and price target.
  • Earnings Growth

    Earnings for NeoGenomics are expected to grow in the coming year, from ($0.20) to $0.09 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NeoGenomics is -8.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NeoGenomics is -8.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NeoGenomics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about NeoGenomics' valuation and earnings.
  • Percentage of Shares Shorted

    3.98% of the float of NeoGenomics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeoGenomics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeoGenomics has recently increased by 17.56%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NeoGenomics does not currently pay a dividend.

  • Dividend Growth

    NeoGenomics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.98% of the float of NeoGenomics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeoGenomics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeoGenomics has recently increased by 17.56%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    NeoGenomics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for NeoGenomics this week, compared to 6 articles on an average week.
  • Search Interest

    14 people have searched for NEO on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NeoGenomics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.40% of the stock of NeoGenomics is held by insiders.

  • Percentage Held by Institutions

    98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NeoGenomics' insider trading history.
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NEO Stock News Headlines

When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.tc pixel
See More Headlines

NEO Stock Analysis - Frequently Asked Questions

NeoGenomics' stock was trading at $16.48 at the start of the year. Since then, NEO shares have decreased by 56.3% and is now trading at $7.21.

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Tuesday, April, 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.06. The company's revenue for the quarter was up 7.6% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of NeoGenomics: Inivata Limited, Trapelo Health, Genesis Acquisition Holding Corp, Genoptix, Clarient Inc, GE Medical Holding AB., Path Labs LLC, and others.

NeoGenomics' top institutional investors include Greenhouse Funds LLLP (5.75%), First Light Asset Management LLC (5.30%), American Century Companies Inc. (2.72%) and Geode Capital Management LLC (2.44%). Insiders that own company stock include Jeffrey Scott Sherman, Warren Stone, Stephen M Kanovsky, Alicia C Olivo, Anthony P Zook, David Brian Perez, Lynn A Tetrault and Michael Aaron Kelly.
View institutional ownership trends
.

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeoGenomics investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
4/29/2025
Today
8/28/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Business Services
Current Symbol
NASDAQ:NEO
CIK
1077183
Employees
2,200
Year Founded
2002

Price Target and Rating

High Price Target
$22.00
Low Price Target
$8.00
Potential Upside/Downside
+78.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.81)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$78.73 million
Net Margins
-15.10%
Pretax Margin
-15.30%
Return on Equity
-2.72%
Return on Assets
-1.54%

Debt

Debt-to-Equity Ratio
0.40
Current Ratio
3.92
Quick Ratio
3.58

Sales & Book Value

Annual Sales
$660.57 million
Price / Sales
1.40
Cash Flow
$0.47 per share
Price / Cash Flow
15.27
Book Value
$6.61 per share
Price / Book
1.08

Miscellaneous

Outstanding Shares
129,180,000
Free Float
126,079,000
Market Cap
$921.70 million
Optionable
Optionable
Beta
1.54

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:NEO) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners